NTLA Intellia Therapeutics, Inc
XNAS
11.65
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NTLA
$11.65
—
Key stats
$11.65
Pre-market
$11.30
-3.00%
- 52-Week Range
- $7.95 – $26.90
- YTD
- +26.49%
- IV Rank (30D)
- 24.21
- Straddle Price
- $2.05
- P/C Vol Ratio
- 0.47
- Market Cap
- $1.7B
- Open
- $11.84
- Day Range
- $11.55 – $11.91
- Volume
- 2,828,831
- Prev Close
- $11.84
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.72 |
| Cost of Equity (CAPM) | 14.59% (VRP-adj) |
| WACC | 14.59% |
| Volatility Risk Premium | +45.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +5.6% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.06 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.3B |
| Return on Equity (TTM) | -55.0% |
| Book / Price | 48.4% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -527.6% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $12.24 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $12.00 |
| Bollinger Width / SMA20 | 132.7% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: BMRA, CLDX, LNTH, MYGN, NEOG, QDEL
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
70%
20-Day Fair Value
≈ by Nov 20, 2026
$11.59
α -0.5%
rank 51%
conviction
36%
40-Day Fair Value
≈ by Dec 21, 2026
$11.73
α +0.7%
rank 49%
conviction
20%
60-Day Fair Value
≈ by Jan 19, 2027
$11.91
α +2.3%
rank 51%
conviction
70%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | median 16.7× · 3 peers |
| Peer P/B | $11.02 | 23% | median 2.0× · 6 peers |
| Peer P/S | $1.49 | 23% | median 2.4× · 6 peers |
| Market Anchor (SMA50) | $12.24 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $12.27 | 54% | 18 strikes · skew -0.10 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (2835) · industry map
- Exchange
- XNAS
- Market Cap
- $1.7B
- Employees
- 377
- List Date
- 2016-05-06
- CIK
- 0001652130
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($0.82) (7 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.intelliatx.com
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema,…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 12.00% | -20.52% | 22.48% | -22.71% | -15.55% | 42.78% | 3.08% |
| Feb | -5.75% | -0.95% | -6.91% | 27.16% | 5.77% | 5.51% | 4.14% |
| Mar | 25.34% | -8.99% | -8.54% | -15.77% | -24.76% | -16.97% | -8.28% |
| Apr | -4.11% | -35.60% | 1.78% | -21.38% | 33.28% | 1.58% | -4.08% |
| May | 1.54% | -10.60% | -1.27% | -4.98% | -20.49% | 6.11% | -4.95% |
| Jun | 119.60% | 20.77% | 6.87% | -4.85% | 31.01% | 23.23% | 32.77% |
| Jul | -17.36% | 19.90% | 3.98% | 16.64% | 17.81% | -38.23% | 0.46% |
| Aug | 17.54% | -4.27% | -8.50% | -10.74% | -1.17% | 18.20% | 1.84% |
| Sep | -18.22% | -6.69% | -16.11% | -4.95% | 51.49% | -4.93% | 0.10% |
| Oct | -0.81% | -5.46% | -14.82% | -25.94% | -32.73% | -3.88%* | -13.94% |
| Nov | -15.75% | -3.29% | 16.20% | 5.47% | -31.22% | -- | -5.72% |
| Dec | 10.59% | -23.82% | -1.13% | -25.87% | 6.77% | -- | -6.69% |
| Total | 107.69% | -62.84% | -12.53% | -66.28% | -18.70% | 10.85% | -6.97% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $12.00
SMA 50: $12.24
SMA 200: $13.04
Current: $11.65
EMA 12: $11.85
EMA 26: $12.01
MACD: -0.1609 | Signal: -0.0582
BEARISH
ADX (14): 12.77
RANGE
+DI: 18.02
−DI: 19.54
Momentum Oscillators
RSI (14): 45.77
NEUTRAL
Stoch %K: 33.05
Stoch %D: 27.74
Williams %R: -68.64
Volume & Volatility
BB Upper: $12.96
BB Lower: $11.05
NEUTRAL
OBV: -5,409,876
Vol SMA 20: 5,810,233
Vol ROC: -65.96%
ATR: $0.71
True Range: $0.36
HV 20: 56.7%
HV 30: 54.3%
HV 60: 58.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
NTLA (Intellia Therapeutics) - Comprehensive Stock Analysis
Executive Summary
Overall Assessment: BEARISH | Confidence Level: 6/10
Investment Thesis: Intellia Therapeutics presents a conflicted technical setup with bearish momentum indicators contradicting recent positive news catalysts. While the company has secured a $400M non-dilutive debt facility and attracted institutional interest (Cathie Wood), the stock is trading below all major moving averages with deteriorating volume, negative MACD, and elevated high-beta risk (2.19). The options market is pricing downside risk, making this a high-risk/high-reward biotech play dependent on near-term clinical or partnership developments.
Key Drivers:
- Positive: $400M OrbiMed debt facility removes near-term financing concerns; gene editing sector tailwinds; recent 7.6% rally suggests potential accumulation
- Key Risks: Trading below all major MAs; negative MACD divergence; severely depressed volume (-82.95% RoC); put/call volume ratio 1.47 indicating bearish positioning; high beta (2.19) amplifies downside in market corrections
Recent News Sentiment Impact: Positive news flow (debt facility, Cathie Wood buying, sector growth) occurred 6-8 weeks prior to current date. The most recent headline (Oct 9, 2026) notes a 7.6% rally but questions "further upside," suggesting exhaustion. News tailwinds appear already priced in, with technical deterioration suggesting momentum fading.
Technical Analysis
Trend Direction
| Timeframe | Status | Interpretation | |-----------|--------|-----------------| | Short-term (1-4 weeks) | BEARISH | Price $11.84 below all moving averages (SMA20: $12.04, SMA50: $12.25, SMA200: $13.02); EMA 12/26 bearish alignment | | Medium-term (1-3 months) | BEARISH | Consistent downtrend from SMA200 ($13.02); -$1.18 below 200-day average (-9.1% below long-term MA) | | Long-term (3-12 months) | BEARISH | Stock trading 9.1% below 200-day MA indicates sustained weakness; no sign of reversal pattern yet |
Support & Resistance Levels
Resistance (Upside):
- Primary: $12.25 (SMA 50) — Immediate barrier to trend reversal
- Secondary: $12.99 (Bollinger Upper Band) — Recent 7.6% rally challenge; overbought threshold
- Strong Resistance: $13.02 (SMA 200) — Must close above to confirm uptrend reversal
Support (Downside):
- Primary: $11.08 (Bollinger Lower Band) — Technical floor; 6.4% downside from current
- Secondary: $10.34 area (implied from ATR of $0.74 below recent lows) — Stop-loss clustering zone
- Critical: $10.00 psychological level — Major capitulation zone
Momentum Signals
RSI (14): 47.66 — NEUTRAL
- Not overbought (>70) or oversold (<30)
- Positioned in neutral zone but biased toward bear side (below 50)
- Lack of extreme readings suggests no imminent reversal, consistent with ranging/consolidating market
- Interpretation: No momentum cushion; vulnerable to downside acceleration below 40
MACD: -0.15 / Signal: -0.07 / Histogram: -0.09 — BEARISH
- Negative Histogram (-0.09): MACD line below signal line = bearish crossover in effect
- MACD remains negative with widening divergence, not yet showing recovery
- No bullish crossover imminent; histogram trending more negative suggests continued bearish momentum
- Interpretation: Bearish momentum continuation; buyers have lost control
Stochastic Oscillators: %K 29.73 / %D 21.14 — OVERSOLD SIGNAL (Potential Buy Setup)
- %K below %D and both in oversold territory (<30)
- This is the only bullish technical signal, suggesting potential near-term bounce/reversal trade
- However, overbought readings must follow for confirmation; current setup is "capitulation bounce" zone
- Interpretation: Suggests exhaustion selloff; short-term tactical bounce possible, but no trend reversal confirmation yet
Williams %R: -60.81 — BEARISH
- In lower half of range (-100 to 0), confirming weakness
- Not at extreme oversold (-100), indicating more downside room possible
- Interpretation: Weakness present but not yet capitulation; downside bias intact
Bollinger Bands: Width 15.81 — NEUTRAL/SQUEEZE
- Band width is moderate (neither wide squeeze nor extreme expansion)
- Price ($11.84) is between lower band ($11.08) and middle band ($12.04), slightly closer to lower
- Interpretation: Potential for volatility expansion in either direction; current positioning suggests vulnerability to lower band test
Volume Analysis
Volume Metrics:
- Volume SMA 20: 5,818,032 shares average
- Volume Rate of Change: -82.95% — SEVERELY DEPRESSED
- On-Balance Volume (OBV): -6,927,145 (negative cumulative) — Institutional selling pressure building
- Expected Move (31 DTE): $2.03 (17.1% range) — Normal for biotech, reflects elevated IV
Institutional Interest Assessment:
- Extreme Volume Deterioration: -82.95% RoC indicates volume has collapsed to barely 17% of 20-day average
- This severe volume weakness is RED FLAG for institutional interest/support
- Negative OBV accumulation suggests institutional unwinding despite positive news
- Combined with put/call volume 1.47, suggests institutions rotating OUT of NTLA
- Interpretation: Lack of volume on rallies; no accumulation despite recent positive catalysts; distribution pattern evident
News & Sentiment Analysis
Recent Headlines Summary
| Date | Headline | Sentiment | Relevance | |------|----------|-----------|-----------| | 2026-10-09 | Soars 7.6%: Is Further Upside Left? | NEUTRAL | Recent rally exhaustion question; near-term top signal | | 2026-09-17 | Aerska Advisory Board Appointment | NEUTRAL | Minor organizational news; limited material impact | | 2026-09-04 | $400M OrbiMed Non-Dilutive Debt | POSITIVE | Removes financing risk; strong validation by tier-1 investor | | 2026-09-04 | Morgan Stanley Healthcare Conference | POSITIVE | Investor visibility; mainstream financial coverage | | 2026-08-31 | Cathie Wood Buying (ARK) | POSITIVE | High-profile institutional accumulation signal | | 2026-07-03 | Gene Editing Sector 12.5% CAGR Growth | POSITIVE | Tailwind narrative; industry fundamentals supportive |
Sentiment Assessment
Aggregate Sentiment: POSITIVE to NEUTRAL (Weakening)
- 4 of 6 recent headlines positive (debt, conferences, Cathie Wood, sector growth)
- Critical Timing Issue: Positive catalysts (debt, Cathie Wood) occurred 6-8 weeks ago; momentum has faded into current date
- Most recent headline (Oct 9) explicitly questions "further upside," suggesting analyst skepticism post-rally
- Divergence: Positive news NOT reflected in technical setup → News already priced in
Catalyst Identification
Immediate Catalysts (1-7 days):
- None identified in available data
- Options market pricing $2.03 expected move suggests anticipation of announcement (possibly conference presentation outcomes)
Near-term Catalysts (1-4 weeks):
- Next Earnings: November 5, 2026 (27 days away) — CRITICAL CATALYST
- Quarterly results will test whether debt facility improves cash burn/runway narrative
- Gene editing clinical trial updates expected in biotech cycles
- Prior earnings: 2026-08-06 (2 months ago), 2026-04-30, 2026-02-26
- Historical: Biotech earnings often volatile; could trigger 7-10% swing
**Medium-term Catalysts (1-3 months
Generated
News
All NTLA news →
Earnings History
28 of 28 under expected move
Avg Expected Move
13.47%
Avg Actual Move
3.77%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-07 | After-Close | 13.81% | 1.14% | 0.08x | Within |
| 2021-02-25 | After-Close | 19.49% | 5.20% | 0.27x | Within |
| 2021-05-06 | After-Close | 12.14% | 1.90% | 0.16x | Within |
| 2021-08-05 | After-Close | 14.59% | 1.30% | 0.09x | Within |
| 2021-11-04 | After-Close | 10.09% | 1.15% | 0.11x | Within |
| 2022-01-06 | After-Close | 13.68% | 1.12% | 0.08x | Within |
| 2022-02-24 | After-Close | 21.72% | 10.18% | 0.47x | Within |
| 2022-05-05 | After-Close | 15.85% | 4.92% | 0.31x | Within |
| 2022-08-04 | After-Close | 14.67% | 3.22% | 0.22x | Within |
| 2022-11-03 | After-Close | 12.59% | 1.30% | 0.10x | Within |
| 2023-01-05 | After-Close | 6.70% | 1.78% | 0.27x | Within |
| 2023-02-23 | After-Close | 10.01% | 3.16% | 0.32x | Within |
| 2023-05-04 | After-Close | 11.41% | 0.57% | 0.05x | Within |
| 2023-08-03 | After-Close | 9.80% | 1.33% | 0.14x | Within |
| 2023-11-09 | After-Close | 7.33% | 3.33% | 0.45x | Within |
| 2024-01-04 | After-Close | 11.62% | 3.01% | 0.26x | Within |
| 2024-02-22 | After-Close | 16.11% | 3.97% | 0.25x | Within |
| 2024-05-09 | After-Close | 7.44% | 1.61% | 0.22x | Within |
| 2024-08-08 | After-Close | 6.48% | 4.11% | 0.63x | Within |
| 2024-11-07 | After-Close | 8.12% | 4.56% | 0.56x | Within |
| 2025-01-10 | After-Close | 11.52% | 1.47% | 0.13x | Within |
| 2025-02-27 | Pre-Market | 18.98% | 0.56% | 0.03x | Within |
| 2025-05-08 | After-Close | 14.19% | 1.93% | 0.14x | Within |
| 2025-08-07 | After-Close | 11.34% | 5.85% | 0.52x | Within |
| 2025-11-06 | After-Close | 22.73% | 22.73% | 1.00x | Within |
| 2026-02-26 | Pre-Market | 26.83% | 6.41% | 0.24x | Within |
| 2026-04-30 | After-Close | 14.09% | 1.63% | 0.12x | Within |
| 2026-08-06 | After-Close | 13.79% | 6.23% | 0.45x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
NTLA Options Activity & IV Rank
NTLA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 74.3%
7-DTE IV: —
Expected Move: $2.05
7-DTE Move: $2.05
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 136
Put Volume: 64
P/C Volume: 0.471
BULLISH
Call OI: 4,082
Put OI: 2,718
P/C OI: 0.666
Total OI: 6,800
ATM Options Pricing
ATM Call: $0.90
ATM Put: $1.15
Call %: 7.7%
Put %: 9.9%
Chain Summary
Chain Volume: 1,883
Chain OI: 69,802
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 55th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
55%
vs own history
GEX tilt
+0.19
OI-weighted, today
Vanna tilt
+0.18
δ-sensitivity to IV
Charm tilt
-0.33
δ-decay vs time
Charm tilt -0.33: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 15 ATM contracts, 10k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · ATM 74.6% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)24.2LowOct 21
Straddle Price (30 DTE)$2.05Oct 21
Beta Analysis
Risk Metrics
Beta: 2.1795
Alpha: -72.53%
Correlation: 0.3066
R-Squared: 9.4%
Stock Volatility: 90.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own NTLA
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $23.7M | #630 of 3138 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $8.3M | #1713 of 3716 | +596.2% | 13F | |
| Point72 Hedge fund Steve Cohen | $6.7M | #890 of 1945 | +47.6% | 13F | |
| Citadel Hedge fund Ken Griffin | $2.8M | #2578 of 6285 | -64.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $2.4M | #1297 of 4729 | +0.3% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NTLA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 110,196,500 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
18 filers$110.02M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $36.46M | 33.14% | 2026-06-30 |
| 2 | Caption Management, LLC | $13.52M | 12.28% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $10.00M | 9.09% | 2026-06-30 |
| 4 | UBS Group AG Custodian | $9.94M | 9.03% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $8.48M | 7.70% | 2026-06-30 |
| 6 | DIADEMA PARTNERS LP | $6.77M | 6.15% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $5.52M | 5.02% | 2025-09-30 |
| 8 | Point72 Asset Management, L.P. | $4.86M | 4.42% | 2026-06-30 |
| 9 | Jefferies Financial Group Inc. | $4.47M | 4.06% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $2.65M | 2.41% | 2026-06-30 |
| 11 | IMC-Chicago, LLC Custodian | $2.35M | 2.13% | 2026-06-30 |
| 12 | Walleye Capital LLC | $1.56M | 1.42% | 2026-06-30 |
| 13 | Simplex Trading, LLC Custodian | $1.04M | 0.95% | 2026-06-30 |
| 14 | NOMURA HOLDINGS INC | $1.02M | 0.92% | 2026-06-30 |
| 15 | CAPITAL FUND MANAGEMENT S.A. | $981.36K | 0.89% | 2026-06-30 |
| 16 | Persistent Asset Partners Ltd | $343.96K | 0.31% | 2026-06-30 |
| 17 | Raiffeisen Bank International AG | $67.68K | 0.06% | 2026-06-30 |
| 18 | Walleye Trading LLC | $16.92K | 0.02% | 2026-06-30 |
13 filers$48.86M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $14.53M | 29.74% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $12.64M | 25.87% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $10.06M | 20.59% | 2026-06-30 |
| 4 | Caption Management, LLC | $2.66M | 5.44% | 2026-06-30 |
| 5 | Wolverine Trading, LLC Custodian | $2.25M | 4.60% | 2025-09-30 |
| 6 | CAPITAL FUND MANAGEMENT S.A. | $1.65M | 3.38% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $1.41M | 2.89% | 2026-06-30 |
| 8 | NOMURA HOLDINGS INC | $1.02M | 2.08% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $754.63K | 1.54% | 2026-06-30 |
| 10 | Simplex Trading, LLC Custodian | $720.79K | 1.48% | 2026-06-30 |
| 11 | Walleye Capital LLC | $470.38K | 0.96% | 2026-06-30 |
| 12 | TUDOR INVESTMENT CORP ET AL | $433.15K | 0.89% | 2026-06-30 |
| 13 | Walleye Trading LLC | $263.95K | 0.54% | 2026-06-30 |
NTLA Insider Trading (Form 4)
Latest: 2026-10-06Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Michael P Dube | VP, Chief Accounting Officer | Sell (S) | −1,864 | $12.43 | -$23.2K | EDGAR |
| 2026-08-24 | John M Leonard | President and CEO | Sell (S) | −22,675 | $12.65 | -$286.8K | EDGAR |
| 2026-07-24 | Edward J Dulac III | EVP, Chief Financial Officer | Sell (S) | −8,111 | $11.25 | -$91.2K | EDGAR |
| 2026-07-06 | Edward J Dulac III | EVP, Chief Financial Officer | Sell (S) | −4,677 | $18.00 | -$84.2K | EDGAR |
| 2026-07-06 | Michael P Dube | VP, Chief Accounting Officer | Sell (S) | −2,641 | $16.78 | -$44.3K | EDGAR |
| 2026-06-10 | Fred E Cohen | Director | Award (A) | +9,200 | — | EDGAR | |
| 2026-06-10 | Muna Bhanji | Director | Award (A) | +9,200 | — | EDGAR | |
| 2026-06-10 | Brian Goff | Director | Award (A) | +9,200 | — | EDGAR | |
| 2026-06-10 | Frank Verwiel | Director | Award (A) | +9,200 | — | EDGAR | |
| 2026-06-10 | William J Chase | Director | Award (A) | +9,200 | — | EDGAR | |
| 2026-06-10 | Jesse Goodman | Director | Award (A) | +9,200 | — | EDGAR | |
| 2026-06-10 | Georgia Keresty | Director | Award (A) | +9,200 | — | EDGAR | |
| 2026-03-03 | James Basta | EVP, General Counsel | Mixed | +44,869 | $13.78 | -$16.7K | EDGAR |
| 2026-03-03 | Eliana Clark | EVP, Chief Technical Officer | Mixed | +6,746 | $13.78 | -$8.4K | EDGAR |
| 2026-03-03 | Birgit C Schultes | EVP, Chief Scientific Officer | Award (A) | +39,200 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NTLA Insider Holdings
16 insiders · @ $11.65
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | John M Leonard | President and CEO | 1,208,264 | $14.08M | -$54.97M | 39 | 2026-08-24 |
| 2 | Fred E Cohen | Director | 216,653 | $2.52M | $1.40M | 12 | 2026-06-10 |
| 3 | James Basta | EVP, General Counsel | 158,005 | $1.84M | -$499.7K | 11 | 2026-03-03 |
| 4 | Edward J Dulac III | EVP, Chief Financial Officer | 148,175 | $1.73M | -$338.8K | 7 | 2026-07-24 |
| 5 | William J Chase | Director | 143,893 | $1.68M | $1.00M | 6 | 2026-06-10 |
| 6 | Birgit C Schultes | EVP, Chief Scientific Officer | 137,733 | $1.60M | -$78.9K | 4 | 2026-03-03 |
| 7 | David Lebwohl | EVP, Chief Medical Officer | 131,192 | $1.53M | -$2.37M | 21 | 2026-03-03 |
| 8 | Eliana Clark | EVP, Chief Technical Officer | 93,864 | $1.09M | -$690.4K | 13 | 2026-03-03 |
| 9 | Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | 77,388 | $901.6K | -$19.26M | 16 | 2025-01-07 |
| 10 | Michael P Dube | VP, Chief Accounting Officer | 65,022 | $757.5K | -$207.4K | 10 | 2026-10-06 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NTLA Board & Officers
As of SEC filings through Oct 6, 2026Directors 8
- John M Leonard · since May 5, 2016
- Frank Verwiel · since Jul 24, 2017
- Jesse Goodman · since Oct 29, 2018
- Fred E Cohen · since Jan 23, 2019
- Georgia Keresty · since Apr 9, 2021
- Muna Bhanji · since Apr 28, 2022
- William J Chase · since Apr 14, 2023
- Brian Goff · since Jun 13, 2024
Officers 7
- John M Leonard · President and CEO · listed since May 2018
- Edward J Dulac III · EVP, Chief Financial Officer · since Jul 22, 2024
- David Lebwohl · EVP, Chief Medical Officer · since Apr 30, 2020
- Eliana Clark · EVP, Chief Technical Officer · since Feb 23, 2022
- Michael P Dube · VP, Chief Accounting Officer · listed since Oct 2024
- Birgit C Schultes · EVP, Chief Scientific Officer · since Jan 13, 2025
- James Basta · EVP, General Counsel · since Jun 23, 2021
Changes in the last 10 years (36)
| Jan 13, 2025 | Birgit C Schultes became EVP, Chief Scientific Officer |
| Jan 9, 2025 | The company announced the departure of Laura Sepp-Lorenzino as EVP, Chief Scientific Officer in an SEC filing |
| Oct 4, 2024 | Michael P Dube listed as VP, Chief Accounting Officer (previously Principal Accounting Officer) in SEC filings |
| Jul 22, 2024 | Edward J Dulac III became EVP, Chief Financial Officer |
| Jun 26, 2024 | The company announced the departure of Glenn Goddard as EVP, Chief Financial Officer in an SEC filing |
| Jun 13, 2024 | Brian Goff became a director |
| Apr 10, 2024 | Michael P Dube became Principal Accounting Officer |
| Dec 5, 2023 | The company announced the departure of John F Crowley from the board in an SEC filing |
| Jun 5, 2023 | The company announced the departure of Jean Francois Formela from the board in an SEC filing |
| Apr 14, 2023 | William J Chase became a director |
| Mar 23, 2023 | The company announced the departure of Caroline Dorsa from the board in an SEC filing |
| Apr 28, 2022 | Muna Bhanji became a director |
| Feb 23, 2022 | Eliana Clark became EVP, Chief Technical Officer |
| Dec 20, 2021 | Derek Hicks became EVP, Chief Business Officer |
| Jun 23, 2021 | James Basta became EVP, General Counsel |
| Apr 9, 2021 | Georgia Keresty became a director |
| Oct 2, 2020 | John F Crowley became a director |
| Apr 30, 2020 | David Lebwohl became EVP, Chief Medical Officer |
| Aug 2, 2019 | Andrew Schiermeier listed as EVP, Chief Operating Officer (previously EVP, Dev and Corp Strategy) in SEC filings |
| May 28, 2019 | Laura Sepp-Lorenzino became EVP, Chief Scientific Officer |
| Jan 23, 2019 | Fred E Cohen became a director |
| Dec 20, 2018 | Andrew Schiermeier listed as EVP, Dev and Corp Strategy (previously EVP, Corporate Strategy) in SEC filings |
| Oct 29, 2018 | Jesse Goodman became a director |
| Oct 29, 2018 | Glenn Goddard became EVP, Chief Financial Officer |
| Aug 3, 2018 | John T. Hayes became Senior Director of Finance and Controller, Interim Principal Accounting Officer. |
| May 15, 2018 | John M Leonard listed as President and CEO (previously EVP, R&D) in SEC filings |
| Apr 20, 2018 | Andrew Schiermeier became EVP, Corporate Strategy |
| Jan 30, 2018 | Caribou Biosciences, Inc. reported in an SEC filing no longer being a 10% owner |
| Dec 14, 2017 | Jose E Rivera listed as EVP, General Counsel (previously EVP, General Counsel & Ops) in SEC filings |
| Jul 24, 2017 | Moncef Slaoui became a director |
| Jul 24, 2017 | Frank Verwiel became a director |
| Jan 10, 2017 | Jose E Rivera no longer listed as a 10% owner in SEC filings |
| Jan 10, 2017 | Jose E Rivera listed as EVP, General Counsel & Ops (previously Chief Operating & Legal Offr) in SEC filings |
| Jan 10, 2017 | John M Leonard no longer listed as a 10% owner in SEC filings |
| Jan 10, 2017 | John M Leonard listed as EVP, R&D (previously Chief Medical Officer) in SEC filings |
| Dec 12, 2016 | Graeme Bell became EVP, Chief Financial Officer |
Not reported recently (17)
- Derek Hicks · Last reported as EVP, Chief Business Officer in an SEC filing dated Jan 7, 2025
- Jose E Rivera · Last reported as EVP, General Counsel in an SEC filing dated Apr 2, 2021
- Andrew Schiermeier · Last reported as EVP, Chief Operating Officer in an SEC filing dated Mar 5, 2021
- Perry A Karsen · Last reported as a director in an SEC filing dated Dec 18, 2020
- Novartis Institutes for BioMedical Research, Inc. · Last reported as a 10% owner in an SEC filing dated Feb 14, 2019
- Novartis Ag · Last reported as a 10% owner in an SEC filing dated Feb 14, 2019
- John T. Hayes · Last reported as Senior Director of Finance and Controller, Interim Principal Accounting Officer. in an SEC filing dated Aug 10, 2018
- Graeme Bell · Last reported as EVP, Chief Financial Officer in an SEC filing dated Mar 30, 2018
- Nessan Bermingham · Last reported as a director in an SEC filing dated Dec 14, 2017
- Moncef Slaoui · Last reported as a director in an SEC filing dated Jul 25, 2017
- Atlas Venture Fund IX, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 11, 2017
- Atlas Venture Associates IX, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 11, 2017
- Atlas Venture Associates IX, LLC · Last reported as a 10% owner in an SEC filing dated Jul 11, 2017
- Carl L Gordon · Last reported as a director in an SEC filing dated May 19, 2017
- Nicole Heifner · Last reported as Principal Accounting Officer in an SEC filing dated Jan 10, 2017
- David V Morrissey · Last reported as Chief Technology Officer in an SEC filing dated Jan 10, 2017
- Thomas M. Barnes · Last reported as Chief Scientific Officer in an SEC filing dated Jan 10, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
NTLA Proposed Insider Sales (Form 144)
Latest: 2026-10-05
? Form 144 Guide
Last 30d:
1 filing
· $736K notice value
· Last 90d:
2 filings
· $1.0M notice value
· 2 unique filers
· 50% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
ELIANA CLARK (1, $736K) · LEONARD JOHN M (1, $294K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-05 | ELIANA CLARK | Officer | 57,750 | $736.3K | 2026-10-05 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-20 | LEONARD JOHN M | Officer, Director | 22,675 | $293.6K | 2026-08-20 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-07-02 | EDWARD DULAC | Officer | 4,677 | $80.6K | 2026-07-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-11 | LEONARD JOHN M | Officer, Director | 88,146 | $822.4K | 2025-12-11 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2024-01-08 | Sepp-Lorenzino Laura | Officer | 2,275 | $64.1K | 2024-01-08 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2023-12-07 | John F. Crowley | Former Director | 32,791 | $506.7K | 2023-12-06 | E*Trade Financial Corporation | — | EDGAR |
| 2023-07-31 | MUNA BHANJI | Director | 265 | $11.2K | 2023-07-31 | E*TRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2023-07-06 | MUNA BHANJI | Director | 1,867 | $73.4K | 2023-07-06 | E*TRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2023-06-20 | ELIANA CLARK | Officer | 5,000 | $225.0K | 2023-06-20 | E*TRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
71 ETFs hold NTLA
25 shown · $321.67M total exposure · 0.06% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.51% | $52.9M | $10.4B | 2026-10-20 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $52.1M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.06% | $41.3M | $75.1B | 2026-10-20 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.02% | $38.1M | — | 2026-09-30 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.05% | $21.2M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $19.1M | — | 2026-09-30 |
| 7 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.11% | $15.1M | $13.7B | 2026-10-20 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.11% | $12.2M | $11.0B | 2026-10-20 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.05% | $9.6M | — | 2026-09-30 |
| 10 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.03% | $9.5M | — | 2026-10-20 |
| 11 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.04% | $8.9M | — | 2026-05-31 |
| 12 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $6.9M | — | 2026-10-20 |
| 13 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.08% | $5.1M | $6.6B | 2026-10-20 |
| 14 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $4.9M | — | 2026-09-30 |
| 15 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.06% | $4.7M | — | 2026-10-20 |
| 16 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.13% | $3.5M | — | 2026-07-31 |
| 17 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.08% | $2.6M | $3.1B | 2026-10-20 |
| 18 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $2.3M | $97.4B | 2026-10-20 |
| 19 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.09% | $2.3M | $2.5B | 2026-10-20 |
| 20 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.34% | $2.2M | — | 2026-10-21 |
| 21 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $1.8M | — | 2026-10-20 |
| 22 | SEIS SEI Select Small Cap ETF | Nport | 0.26% | $1.5M | — | 2026-06-30 |
| 23 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 0.43% | $1.4M | $325.4M | 2026-10-20 |
| 24 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.09% | $1.3M | — | 2026-09-30 |
| 25 | GNOM Global X Genomics & Biotechnology ETF | Global X | 0.95% | $1.0M | — | 2026-10-21 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-3.53
TTM Revenue
$66.09M
TTM Net Income
$-394.60M
TTM Op. Cash Flow
$-363.15M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $15.05M | $-96.23M | $-0.81 | $-117.35M |
| Q4 '25 | 2025-12-31 | $23.02M | $-95.79M | $-0.82 | $-69.28M |
| Q3 '25 | 2025-09-30 | $13.78M | $-101.32M | $-0.92 | $-76.90M |
| Q2 '25 | 2025-06-30 | $14.24M | $-101.25M | $-0.98 | $-99.62M |
| Q1 '25 | 2025-03-31 | $16.63M | $-114.33M | $-1.10 | $-148.93M |
| Q4 '24 | 2024-12-31 | $12.87M | $-128.90M | $-1.26 | $-85.19M |
| Q3 '24 | 2024-09-30 | $9.11M | $-135.71M | $-1.34 | $-84.84M |
| Q2 '24 | 2024-06-30 | $6.96M | $-146.97M | $-1.52 | $-58.19M |
| Q1 '24 | 2024-03-31 | $28.93M | $-107.44M | $-1.12 | $-120.66M |
| Q4 '23 | 2023-12-31 | $-1.92M | $-132.16M | $-1.46 | $-93.05M |
| Q3 '23 | 2023-09-30 | $11.99M | $-122.22M | $-1.38 | $-101.48M |
| Q2 '23 | 2023-06-30 | $13.59M | $-123.68M | $-1.40 | $-90.22M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.07
P/S
19.42
EV/EBITDA
—
EV/Sales
17.39
ROE
-63.5%
ROA
-52.0%
Div Yield
0.00%
FCF Yield
-28.29%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.28B
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
45.11M
SI % of Float
39.21%
Days to Cover
9.47
Short Vol Ratio
46.9%
Free Float
115.06M
Float %
82.1%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14